[1]
Pugliese A. Advances in the etiology and mechanisms of type 1 diabetes. Discov Med 2014; 18: 141-50.
[2]
Rich SS, Concannon P, Erlich H, et al. The type 1 diabetes genetics consortium. Ann N Y Acad Sci 2006; 1079: 1-8.
[3]
Ge Y, Paisie TK, Newman JRB, McIntyre LM, Concannon P. UBASH3A Mediates risk for type 1 diabetes through inhibition of T-cell receptor-induced NF-κB signaling. Diabetes 2017; 66: 2033-43.
[4]
Bakay M, Pandey R, Hakonarson H. Genes involved in type 1 diabetes: an update. Genes (Basel) 2013; 4: 499-521.
[5]
Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase. Lyp Blood 1999; 93: 2013-24.
[6]
Yu X, Sun JP, He Y, Guo X, Liu S, Zhou B, et al. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc Natl Acad Sci USA 2007; 104: 19767-72.
[7]
Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36: 337-8.
[8]
Petrone A, Suraci C, Capizzi M, et al. The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: non insulin requiring autoimmune diabetes (NIRAD) study 3. Diabetes Care 2008; 31: 534-8.
[9]
Dultz G, Matheis N, Dittmar M, Röhrig B, Bender K, Kahaly GJ. The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes. Thyroid 2009; 19: 143-8.
[10]
Zheng W, She JX. Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes. Diabetes 2005; 54: 906-8.
[11]
Smyth D, Cooper JD, Collins JE, et al. PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes. Diabetes 2008; 57: 1730-7.
[12]
Douroudis K, Prans E, Haller K, et al. Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population. Tissue Antigens 2008; 72: 425-30.
[13]
Peng H, Zhou M, Xu WD, et al. Association of PTPN22 C1858T polymorphism and type 1 diabetes: A meta-analysis. Immunol Invest 2012; 41: 484-96.
[14]
Tang S, Peng W, Wang C, Tang H, Zhang Q. Association of the PTPN22 gene (+1858C/T,-1123G/C) polymorphisms with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 2012; 97: 446-52.
[15]
Lee YH, Song GG. Meta-analysis of the family-based association between the PTPN22 C1858T polymorphism and type 1 diabetes. Mol Biol Rep 2013; 40: 211-5.
[16]
Zheng J, Ibrahim S, Petersen F, Yu X. Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue. Genes Immun 2012; 13: 641-52.
[17]
Wang XF, Chen ZX, Shao YC, et al. Population-based and family-based studies on the protein tyrosine phosphatase non-receptor 22 gene polymorphism and type 1 diabetes: a meta-analysis. Gene 2013; 517: 191-6.
[18]
Xuan C, Lun LM, Zhao JX, et al. PTPN22 gene polymorphism (C1858T) is associated with susceptibility to type 1 diabetes: a meta-analysis of 19, 495 cases and 25, 341 controls. Ann Hum Genet 2013; 77: 191-203.
[19]
Blasetti A, Di Giulio C, Tumini S, et al. Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes. Pharmacogenomics J 2017; 17: 186-91.
[20]
Abdelrahman HM, Sherief LM, Abd Elrahman DM, Alghobashy A, Elsaadani HF, Mohamed RH. The association of PTPN22 (rs2476601) and IL2RA (rs11594656) polymorphisms with T1D in Egyptian children. Hum Immunol 2016; 77: 682-6.
[21]
Liu HW, Xu RY, Sun RP, et al. Association of PTPN22 gene polymorphism with type 1 diabetes mellitus in Chinese children and adolescents. Genet Mol Res 2015; 14: 63-8.
[22]
Zervou MI, Castro-Giner F, Sidiropoulos P, Boumpas DT, Tosca AD, Krueger-Krasagakis S. The protein tyrosine phosphatase, non-receptor type 22 R620Wpolymorphismdoes not confer susceptibility to psoriasis in the genetic homogeneous population of Crete. Genet Test Mol Biomarkers 2010; 14: 107-11.
[23]
Eliopoulos E, Zervou MI, Andreou A, et al. Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete. Lupus 2011; 20: 501-6.
[24]
Giza S, Goulas A, Gbandi E, et al. The Role of PTPN22 C1858T gene polymorphism in diabetes mellitus type 1: first evaluation in greek children and adolescents. BioMed Res Int 2013; 2013721604
[25]
Saccucci P, Del Duca E, Rapini N, et al. Association between PTPN22 C1858T and type 1 diabetes: a replication in continental Italy. Tissue Antigens 2008; 71: 234-7.
[26]
Steck AK, Liu SY, McFann K, et al. Association of the PTPN22/LYP gene with type 1 diabetes. Pediatr Diabetes 2006; 7: 274-8.
[27]
Smyth DJ, Cooper JD, Howson JM, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53: 3020-3.
[28]
Zhernakova A, Eerligh P, Wijmenga C, Barrera P, Roep BO, Koeleman BP. Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population. Genes Immun 2005; 6: 459-61.
[29]
Gomez LM, Anaya JM, Gonzalez CI, et al. PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases. Genes Immun 2005; 6: 628-31.
[30]
Chagastelles PC, Romitti M, Trein MR, Bandinelli E, Tschiedel B, Nardi NB. Association between the 1858T allele of the protein tyrosine phosphatase nonreceptor type 22 and type 1 diabetes in a Brazilian population. Tissue Antigens 2010; 76: 144-8.
[31]
Nielsen C, Hansen D, Husby S, Lillevang ST. Sexspecific association of the human PTPN22 1858T-allele with type 1 diabetes. Int J Immunogenet 2007; 34: 469-73.
[32]
Santiago JL, Martínez A, de la Calle H, et al. Susceptibility to type 1 diabetes conferred by the PTPN22 C1858T polymorphism in the Spanish population. BMC Med Genet 2007; 8: 54.
[33]
Fedetz M, Matesanz F, Caro-Maldonado A, et al. The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population. Tissue Antigens 2006; 67: 430-3.
[34]
Kahles H, Ramos-Lopez E, Lange B, Zwermann O, Reincke M, Badenhoop K. Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto’s thyroiditis or Addison’s disease in the German population. Eur J Endocrinol 2005; 153: 895-9.
[35]
Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008; 57: 1084-92.
[36]
Kordonouri O, Hartmann R, Badenhoop K, Kahles H, Ilonen J. PTPN22 1858T allele is associated with younger age at onset of type 1 diabetes and is not related to subsequent thyroid autoimmunity. Hum Immunol 2010; 71: 731-2.
[37]
Howson JM, Walker NM, Smyth DJ, Todd JA. Analysis of 19 genes for association with type I diabetes in the Type I Diabetes Genetics Consortium families. Genes Immun 2009; 10: S74-84.
[38]
Nielsen LB, Pörksen S, Andersen ML, et al. The PTPN22 C1858T gene variant is associated with proinsulin in new-onset type 1 diabetes. BMC Med Genet 2011; 12: 41.
[39]
Hadžija MP, Korolija M, Vukadinović G, Hadžija M. Association of TNF-α and PTPN22 SNPs with the risk and clinical outcome of type 1 diabetes. Cent Eur J Biol 2013; 8: 513-9.
